Literature DB >> 7075113

Diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone, plasma and cerebrospinal fluid kinetics.

N R Bachur, J M Collins, J A Kelley, D A Van Echo, R S Kaplan, M Whitacre.   

Abstract

Plasma and cerebrospinal fluid (CSF) kinetics of diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone (AZQ), were evaluated after intravenous injection in patients with implanted Ommaya reservoirs. After a 30-min infusion plasma disappearance was very rapid, with a disposition half-life of 2 to 6 min and on elimination half-life of 25 to 35 min. Area under the concentration-time curve for CSF was 22% to 42% of the corresponding plasma area. Based upon total plasma AZQ concentration, volume of distribution for AZQ was 2.0 to 10.0 l/m2. Plasma binding of AZQ was 79% in one normal subject. When the effect of plasma binding is considered, distribution volumes are more plausible and it appears that free plasma AZQ is completely available to the CSF.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7075113     DOI: 10.1038/clpt.1982.90

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

Review 1.  New cytotoxic drugs for intrathecal administration.

Authors:  S M Blaney; D G Poplack
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

2.  Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome.

Authors:  Jai Grewal; Marlon Saria; Harpreet K Grewal; Santosh Kesari
Journal:  Clin Investig (Lond)       Date:  2011-10

3.  Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human malignant glioma.

Authors:  J Maral; M Poisson; B F Pertuiset; P Mashaly; M Weil; C Jacquillat; A J Grillo-Lopez
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

4.  Stability of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZQ; NSC 224070) in aqueous solutions by high-performance liquid chromatography.

Authors:  A G Bosanquet; S B McLoughlin
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

5.  A phase II trial of diaziquone in patients with head and neck cancer.

Authors:  F Muñiz; E Vélez-García; J A Neidhart; J F Bender; M Becker; A J Grillo-Lopez
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Phase II study of aziridinylbenzoquinone (AZQ) in patients with central nervous system malignancies: a Southwest Oncology Group Study.

Authors:  S A Taylor; J D McCracken; H J Eyre; R M O'Bryan; B A Neilan
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.